Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1988 Jul;56(7):1829-30.
doi: 10.1128/iai.56.7.1829-1830.1988.

Immunization with a Pseudomonas aeruginosa immunotype 5 O polysaccharide-toxin A conjugate vaccine: effect of a booster dose on antibody levels in humans

Affiliations
Clinical Trial

Immunization with a Pseudomonas aeruginosa immunotype 5 O polysaccharide-toxin A conjugate vaccine: effect of a booster dose on antibody levels in humans

S J Cryz Jr et al. Infect Immun. 1988 Jul.

Abstract

Healthy adult volunteers were vaccinated on day 0 and 28 and at 15 months with a Pseudomonas aeruginosa immunotype 5 O polysaccharide-toxin A conjugate vaccine. Immunization resulted in mild, transient local reactions in less than 20% of the subjects. Maximal immunoglobulin G (IgG) antibody titers to both toxin A and lipopolysaccharide (LPS) as determined by enzyme-linked immunosorbent assay were seen at day 42, at which time 50% of the vaccinees showed a fourfold or greater rise in toxin A-neutralizing titers. By 15 months postvaccination, both antitoxin A and anti-LPS IgG antibodies had markedly declined. A booster dose of vaccine administered at 15 months evoked a vigorous anti-toxin A IgG antibody response with 100% of the volunteers showing a fourfold or greater rise in neutralizing antibody titer compared with preimmunization levels. In contrast, there was no significant elevation of anti-LPS IgG antibody levels. At 24 months postimmunization, only anti-toxin A antibody levels were significantly higher than preimmunization levels.

PubMed Disclaimer

Similar articles

Cited by

References

    1. J Infect Dis. 1974 Nov;130 Suppl(0):S152-8 - PubMed
    1. J Clin Invest. 1979 Feb;63(2):276-86 - PubMed
    1. J Infect Dis. 1980 Oct;142(4):538-46 - PubMed
    1. Lancet. 1980 Dec 13;2(8207):1263-5 - PubMed
    1. Rev Infect Dis. 1983 Mar-Apr;5(2):279-313 - PubMed

Publication types

MeSH terms

LinkOut - more resources